ARTIDIS employs advanced nanomechanical sensing technology to revolutionize cancer diagnosis and treatment optimization. The ARTIDIS platform utilizes a unique nanomechanical biomarker that captures the physical properties of tumor cells and their surrounding microenvironment with high precision. This capability allows for rapid differentiation between benign and malignant tissues in under three hours, significantly reducing the anxiety and waiting time typically associated with cancer diagnoses. Additionally, the technology assesses tumor aggressiveness by analyzing factors such as the presence of soft cells that can metastasize and the heterogeneity of tumor tissue, which influences treatment permeability.

Beyond oncology, ARTIDIS's technology has broader applications in various medical fields, including ophthalmology, orthopedics, dermatology, and biomedical engineering. By integrating the nanomechanical biomarker with patient clinical data, the ARTIDISNET platform aids healthcare professionals in developing personalized treatment plans, thereby enhancing patient outcomes and minimizing the risks of overtreatment. This innovative approach not only streamlines the diagnostic process but also empowers clinicians with the tools necessary for effective decision-making in patient care.

Switzerland

ARTIDIS AG is a clinical stage medical technology company developing the ﬁrst nanotechnology platform for tissue analysis combined with a digital data platform, intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization.

ARTIDIS

Company Details